Recruiting

Resveratrol

Sponsor:

University of Central Florida

Code:

NCT06723119

Conditions

Effect of Resveratrol on Performance and Recovery

Eligibility Criteria

Sex: Male

Age: 18 - 40

Healthy Volunteers: Accepted

Interventions

Resveratrol (VRES) 500 mg oral once daily.

Placebo 500 mg oral once daily.

Study Details

Brief summary:

To examine the effects of once daily supplementation with 500mg VeriSperse® resveratrol (VRES) for 17 days on muscle function, delayed onset muscle soreness, systemic concentrations of muscular damage markers and markers of oxidative stress in resistance trained young adult males following a damaging isoinertial squat protocol (ISP).

Conditions

Effect of Resveratrol on Performance and Recovery

Study ID

NCT06723119

Start date

Oct 1, 2024

Status verified date

Nov, 2024

Completion date

Apr 1, 2025

Anticipated

Primary completion date

Apr 1, 2025

Anticipated

Eligibility Criteria

Eligibility Criteria

Sex: Male

Age: 18 - 40

Healthy Volunteers: Accepted

Inclusion Criteria:

  • • Male between the ages of 18-40 years old

  • Healthy, and ready for physical activity as determined by the PAR-Q+, and MHQ.
  • Participants will be required to be recreationally active (defined according to ACSM standards of at least 150 minutes exercise per week).
  • Participants will be required to have been actively resistance training for a minimum of 6 months as defined by 3 resistance training sessions per week with at least one lower body session.
  • Participants must be willing to abstain from the consumption of bananas of non-steroidal anti-inflammatory drugs (NSAIDs) for the duration of their enrollment in study.
  • Participants must be willing to abstain from dietary supplementation that are viewed by study investigators to confound the outcomes of the study (e.g., Creatine). Those currently supplementing must be willing to undergo a 28-day washout prior to beginning study procedures.
  • Participants must be consuming <300 mg·day-1 (Equivalent to 3 cups of coffee per day or 2 16oz cans of Redbull) and willing to keep their caffeine consumption consistent throughout the duration of the study.
  • Participants will be required to have access to the online MyFitnessPal application either via cellphone or computer and be willing to download and maintain the application for the duration of the study.
  • Free from previous or current lower body injuries that are viewed by the investigators to potentially limit ability of the participant to perform the assessments.
  • Willing to abstain from lower body resistance training for the 14 days preceding ET1 and ET2

Exclusion Criteria:

  • • Individual does not provide consent to participate in this study.

  • Inability to perform physical exercise (determined by MHQ, and PAR Q+). That is Answering "Yes" to any question on the PAR-Q +, or having a pre-existing condition such as musculoskeletal injury, back pain, chronic pain etc. that the investigative team perceives will prevent a participant from safely completing the protocol.
  • Not currently participating in at least 150 minutes of physical activity per week.
  • Not currently resistance trained (as defined within the inclusion criteria)
  • Currently taking any performance-enhancing drug (determined from health and activity questionnaire)
  • Currently taking a nutritional supplement known to improve physical performance and not willing refrain form the consumption of the supplement for at least 28-days prior to beginning study procedures.
  • Regularly taking any type of prescription or over-the-counter medication deemed to affect performance, or having any chronic illnesses, which require medical care.
  • Have used nicotine or tobacco at any time within the last three months.
  • Report consuming bananas or NSAIDS at any time during your enrollment in the study.
  • Report daily caffeine consumption >300 mg·day-1
  • Report any lower extremity muscle soreness for visits ET1 and ET2
  • Previous or current lower body injuries viewed by the investigators to potentially limit the ability of the participant to perform the assessments.
  • Inability or unwillingness to consume the provided standardized snacks and meals in their entirety.
  • Inability or unwillingness to adhere to the diet restrictions of the study.
  • Have a food allergy to either of the two provided energy bars.
  • Inability or unwillingness to report all food and beverage consumption during the two 5-day dietary log periods.

Study Design

Enrollment

20 participants

Anticipated

Allocation

Randomized

Intervention Model

Crossover

Primary purpose

Basic Science

Interventions and Outcome Measures

Arms

active comparator: Resveratrol Supplementation

Once daily (immediately upon waking) supplementation with 500mg (2 capsules) VeriSperse® resveratrol (VRES) for 17 days

placebo comparator: Placebo

Once daily (immediately upon waking) supplementation with 500mg (2 capsules) Placebo (maltodextrin) for 17 days

Interventions

Resveratrol (VRES) 500 mg oral once daily.

Resveratrol supplement will be provided in capsule form within a distinctly labeled bottle. Participants will be instructed to consume 2 capsules (500mg) of their assigned supplement with at least 8oz of water immediately upon waking for 17 days.

Placebo 500 mg oral once daily.

Placebo will be supplement will be provided in capsule form within a distinctly labeled bottle. Participants will be instructed to consume 2 capsules (500mg) of their assigned supplement with at least 8oz of water immediately upon waking for 17 days.

Primary outcome measure

  • Venous Blood Sample Collection - Creatine Kinase [ Time Frame: Visit 2 & visits 6-13 approx=8 weeks ]
  • Venous Blood Sample Collection - C-Reactive protein [ Time Frame: Visit 2 & visits 6-13 approx=8 weeks ]
  • Venous Blood Sample Collection - CBC [ Time Frame: Visit 2 & visits 6-13 approx=8 weeks ]
  • Flow Mediated Dilation (FMD) [ Time Frame: Visit 2 & visits 6-13 approx=8 weeks ]
  • Ultrasound Measurement (MT and EI) [ Time Frame: Visit 2 & visits 6-13 approx=8 weeks ]
  • Active Range of Motion (AROM) [ Time Frame: Visit 2 & visits 6-13 approx=8 weeks ]
  • Pain Pressure Threshold [ Time Frame: Visit 2 & visits 6-13 approx=8 weeks ]
  • Perceived Recovery Scale (PRS) [ Time Frame: Visit 2 & visits 6-13 approx=8 weeks ]
  • Muscle Soreness (MS) [ Time Frame: Visit 2 & visits 6-13 approx=8 weeks ]
  • Maximal Voluntary Isometric Contraction (MVIC) and Rate of Force development (RFD) [ Time Frame: Visit 2 & visits 6-13 approx=8 weeks ]
  • Vertical Jump Protocol (VJ) [ Time Frame: Visit 2 & visits 6-13 approx=8 weeks ]
  • Isoinertial Squat Protocol (ISP) [ Time Frame: Visit 2 & visits 6-13 approx=8 weeks ]

Central Contacts and Locations

Central contacts

Trevor Dufner

701-205-8690trevor.dufner@ucf.edu

Locations

University of Central Florida EPIC Lab

Recruiting

Orlando, Florida, United States, 32816

Contacts

Adam Wells. Dr.

407-823-3906adam.wells@ucf.edu

Principal Investigator:

Trevor Dufner

More Information

Sponsor

University of Central Florida

Last update posted

Dec 9, 2024

Last verified

Nov, 2024

Trial information was received from ClinicalTrials.gov and was last updated on 2026-09-10. This information was provided to ClinicalTrials.gov by University of Central Florida on 2024-12-09.